ABBV AbbVie Inc.

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

The Vanguard Group, Inc. (IRSH)
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

31-March-2020 / 14:16 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Ap19

 

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH IN INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.  KEY INFORMATION

 

Name of person dealing (Note 1)

The Vanguard Group, Inc.

Company dealt in

AbbVie plc

Class of relevant security to which the dealings being disclosed relate (Note 2)

US$0.01 common stock

Date of dealing

30 March 2020

 

2.  INTERESTS AND SHORT POSITIONS

 

(a)  Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

Long

Short

 

Numbers

(%)

Numbers

(%)

(1) Relevant securities

125,547,647

8.50%

39,403

0.00%

(2) Derivatives (other than options)

 

 

(3) Options and agreements to purchase/sell

 

 

Total

125,547,647

8.50%

39,403

0.00%
           

 

(b)  Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:

Long

Short

 

Numbers

(%)

Numbers

(%)

(1) Relevant securities

 

 

 

 

(2) Derivatives (other than options)

 

 

(3) Options and agreements to purchase/sell

 

 

Total

 

 

 

 

 

Ap20

 

1.  Dealings (Note 4)

 

(a)  Purchases and sales

Purchase/sale

Number of relevant securities

Price per unit (Note 5)

Sale

46,629

72.66 USD

Sale

35,282

72.67 USD

Purchase

171,321

72.67 USD

 

 

(b)  Derivatives transactions (other than options transactions)

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(Note 5)

Not Applicable

 

 

 

 

 

(c)  Options transactions in respect of existing relevant securities

 

(i)  Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

Not Applicable

 

 

 

 

 

 

 

 

(ii)  Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

 

Not Applicable

 

 

 

 

(e)  Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

Not Applicable

 

 

Ap21

 

2.  OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached? (Note 9)                           NO

 

Date of disclosure

31 March 2020

Contact name

Shawn Acker

Telephone number

001-610-669-8989

If a connected EFM, name of offeree/offeror with which connected

 

If a connected EFM, state nature of connection (Note 10)

 

 

 
Category Code: RET - AbbVie plc
TIDM: IRSH
LEI Code: 5493002789CX3L0CJP65
Sequence No.: 55805
EQS News ID: 1012075

 
End of Announcement EQS News Service

fncls.ssp?fn=show_t_gif&application_id=1012075&application_name=news&site_id=research_pool
EN
31/03/2020

Underlying

ABBVAbbVie Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AbbVie Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 43.84
NTRA NATERA
FMS Fresenius Medic... ... (+7)

Vermilion Compass: Weekly Equity Strategy

S&P 500 and Nasdaq 100 Testing Prior 2022 Highs Since late-February (2/25/25 Compass) we expected an 8-10% pullback to provide a buying opportunity. But that all changed in last week's Compass (4/1/25), when we downgraded our outlook to bearish/cautious, citing several concerning developments (SPX and QQQ failure at 200-day MAs, bear flag breakdowns across major indexes targeting 5100-5200 on SPX, high yield spreads widening above 355bps, major tops on market leaders NVDA and META, semiconducto...

NTRA NATERA
FMS FRESENIUS MEDICAL CARE AG & CO. KGAA ADS
DGX QUEST DIAGNOSTICS INCORPORATED
BMY BRISTOL-MYERS SQUIBB COMPANY
ABBV ABBVIE INC.
ABT ABBOTT LABORATORIES
LH LABCORP HOLDINGS INC
04/08/25 April 8, 2025 1 EN
Free Trial
ABBV ABBVIE INC.

Abbvie Inc: 2 directors

Two Directors at Abbvie Inc sold/sold after exercising options/gave away 61,288 shares at between 0.000USD and 210.081USD. The significance rating of the trade was 79/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by al...

04/03/25 April 3, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 43.84
MO Altria Group In...
LLY Eli Lilly and C... ... (+15)

Vermilion Compass: Weekly Equity Strategy

Near-Term Downside Likely Following False Breakouts Our long-term outlook remains bullish as long as the S&P 500 remains above 5770-5850 and 5600-5670 (worst case), and we are buyers at these levels. With that said, we see potential for near-term downside as the S&P 500, Nasdaq 100 (QQQ), and FANG+ (FNGS) (1) could not decisively break out to new highs, (2) display bearish false breakouts, (3) have fallen back into their 2+ month trading ranges, (4) are violating their 1+ month uptrends, and (5...

MO ALTRIA GROUP INC
LLY ELI LILLY AND COMPANY
CFSL COCA-COLA FEMSA SAB DE CV (ADR)
JNJ JOHNSON & JOHNSON
BMY BRISTOL-MYERS SQUIBB COMPANY
AKOB EMBOTELLADORA ANDINA S.A. SERIES B ADS
FMX FOMENTO ECONOMICO MEXICANO S.A.B. DE C.V. ADS
BMTA BRITISH AMERICAN TOBACCO PLC ADS
PM PHILIP MORRIS INTERNATIONAL INC.
ABBV ABBVIE INC.
CCHGY COCA-COLA HBC AG
ABT ABBOTT LABORATORIES
AZN ASTRAZENECA PLC ADS
GSK. GLAXOSMITHKLINE PLC CEDEAR
IMBBY IMPERIAL BRANDS PLC
02/25/25 February 25, 2025 1 EN
EUR 157.81
ABBV ABBVIE INC.

Moody's Ratings assigns A3 rating to AbbVie's sr. notes; outlook is po...

Moody's Ratings (Moody's) assigned an A3 rating to the new senior unsecured notes issuance of AbbVie Inc. ("AbbVie"). There are no changes to AbbVie's existing ratings including the A3 senior unsecured rating and the Prime-2 short-term rating, or the positive outlook. Proceeds of the offering will...

02/18/25 February 18, 2025 1 EN
EUR 657.53
ABBV ABBVIE INC.

AbbVie Inc. - September 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

12/12/24 December 12, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch